

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the announcement of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”) dated September 28, 2023 (the “**Announcement**”) in relation to the partial exercise of the Over-allotment Option in respect of an aggregate of 917,800 H Shares of the Company. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

Upon the partial exercise of the Over-allotment Option, the registered capital and the total number of issued Shares of the Company were changed to RMB374,157,695 and 374,157,695 Shares, respectively. To reflect such changes in the registered capital of the Company, corresponding amendments (the “**Amendments**”) were made to the articles of association of the Company (the “**Articles of Association**”).

In accordance with the shareholders’ resolutions of the Company dated June 14, 2022 and amended on June 1, 2023 as disclosed in the prospectus of the Company dated August 24, 2023, the general meeting of the Company has authorized the board of directors of the Company (the “**Board**”) and the person authorized by the Board to make corresponding adjustments and amendments to the Articles of Association based on the actual results of the Global Offering, including but not limited to the wordings, sections, articles and conditions precedent of the Articles of Association, pursuant to which the Company announces the Amendments as set out below. In accordance with the aforementioned authorization granted at the general meeting of the Company, the Amendments do not require additional approval at the general meeting of the Company.

Article No.	Before Amendments	After Amendments
Article 6	The registered capital of the Company is RMB373,239,895.	The registered capital of the Company is RMB373,239,895 RMB374,157,695.
Article 21	Upon completion of the initial public offering of H Shares, assuming that the over-allotment options are not exercised, the total number of the Company's shares is 373,239,895 on the date of listing; assuming that the over-allotment options are fully exercised, the total number of the Company's shares is 375,811,895. All of the Company's shares are ordinary shares.	Upon completion of the initial public offering of H Shares, assuming that the over-allotment options are not exercised, the total number of the Company's shares is 373,239,895 on the date of listing; assuming that the over-allotment options are fully exercised, the total number of the Company's shares is 375,811,895 The total number of the Company's shares is 374,157,695. All of the Company's shares are ordinary shares.

The full text of the amended Articles of Association is available on the Company's website at www.immuneonco.com and the Stock Exchange's website at <http://www.hkexnews.hk>.

Shareholders should be aware that the amended Articles of Association are written in Chinese. In the event of discrepancies between the Chinese version and the English translation of the amended Articles of Association, the Chinese version shall prevail.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
 宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Hong Kong, October 27, 2023

As at the date of this announcement, the Board comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Song Ziyi as executive directors; (ii) Dr. Xu Cong, Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive directors.